EU Committee Supports New Roche and Eli Lilly Meds as Clovis’ Ovarian Cancer Drug is Rejected

July 25, 2022

The European Committee for Medicinal Products for Human Use (CHMP) has given the nod to Eli Lilly for its type 2 diabetes drug Mounjaro and Roche’s macular degeneration drug Vabysmo. Clovis’ Rubraca, a third-line treatment for ovarian cancer, was not reccomended by the committee based on the manufacturer’s request. The drugmaker had already voluntarily pulled the drug in the US due to data linking the drug to increased mortality risk.

According to Kevin Dunleavy, “Another recommendation from CHMP came for expanding the use of Bavarian Nordic’s smallpox vaccine to monkeypox to address the rise in cases in Europe. Imvanex, which was sanctioned in Europe for smallpox in 2013, also has been blessed by CHMP to protect against disease caused by vaccinia virus, which leads to symptoms similar to, but milder than those of smallpox.”

To read more, click here.

(Source: Fierce Pharma, July 22nd, 2022)

Share This Story!